Hans von Faber

Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

Markus Krumbholz, Hans von Faber, F. Steinmeyer et al. · Brain · 2008 · 162 citations

Life Sciences, Immunology, Pathobiology +17

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate

Joachim Havla, Lisa Ann Gerdes, Ingrid Meinl et al. · Journal of Neurology · 2011 · 83 citations

Life Sciences, Neurology, Pharmacotherapy +10

Fingolimod induces neuroprotective factors in human astrocytes

Franziska Hoffmann, Johann Hofereiter, Heike Rübsamen et al. · Journal of Neuroinflammation · 2015 · 83 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Closing the case of <i>APOE</i> in multiple sclerosis: no association with disease risk in over 29 000 subjects: Figure 1

Christina M. Lill, Tian Liu, Brit‐Maren M. Schjeide et al. · Journal of Medical Genetics · 2012 · 34 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Prolonged and symptomatic bradycardia following a single dose of fingolimod

Hans von Faber, Hans-Jörg Fischer, Frank Weber · Multiple Sclerosis Journal · 2012 · 32 citations

Medicine, Neurology, Pharmacotherapy +6